SeaSpine Holdings Corporation (SPNE)
(Delayed Data from NSDQ)
$15.36 USD
+0.73 (4.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.36 USD
+0.73 (4.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
SeaSpine Holdings (SPNE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
SeaSpine (SPNE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for CVS Health (CVS) in Q3 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Q3 earnings might have been affected by issues like lower prescription and soft front store volume due to decline in provider visits.
National Vision (EYE) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.
Tivity Health (TVTY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Strength in digital branding is likely to have aided Tivity Health's (TVTY) performance in the third quarter of 2020 amid coronavirus-led economic doldrums.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
What Makes SeaSpine Holdings (SPNE) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does SeaSpine Holdings (SPNE) have what it takes to be a top stock pick for momentum investors? Let's find out.
SeaSpine's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in SeaSpine.
Moving Average Crossover Alert: SeaSpine Holdings
by Zacks Equity Research
SeaSpine Holdings is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
SeaSpine Holdings (SPNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of 28.57% and 36.82%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SeaSpine Holdings (SPNE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings (SPNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings Enters Oversold Territory
by Zacks Equity Research
SeaSpine Holdings has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
SeaSpine Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
SeaSpine Holdings has been struggling lately, but the selling pressure may be coming to an end soon.
SeaSpine Holdings (SPNE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -2.27% and 0.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
by Zacks Equity Research
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.
CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.
Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.
Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.
Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Align Technology (ALGN) Earnings Beat in Q4, Margins Rise
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.